Logiq Stock Price, News & Analysis

Logiq, Inc. (LGIQ) is a U.S.-headquartered technology company that has evolved from a focus on e-commerce and digital customer acquisition into a broader health and biotechnology platform. Founded in November 2004, Logiq was previously engaged in e-commerce solutions and services and is described as a provider of digital consumer acquisition solutions that simplifies digital advertising for agencies, small and medium-sized businesses, and enterprises. Over time, the company has expanded its strategy to target the medical field, particularly cell and gene therapy, longevity, anti-aging, rejuvenation, and medical devices, while also developing new activities in animal health.

According to multiple company announcements, Logiq historically provided data-driven, end-to-end marketing solutions and software to activate campaigns across multiple channels. Its digital marketing business includes a self-serve ad tech platform with proprietary, AI-powered solutions that allow brands and agencies to advertise across thousands of digital and connected TV publishers. The platform incorporates programmatic advertising, fraud detection, and analytics designed to help clients optimize marketing spend and improve customer acquisition.

Transition from Digital Advertising to Health and Biotech

Logiq reports that it recently sold part of its technology business and decided to change direction by targeting the medical field. The company describes a new focus on cell and gene therapy, longevity, anti-aging, and rejuvenation, supported by acquisitions and planned acquisitions of specialized biotech and medical device businesses. Company communications state that, post-acquisitions, Logiq is expected to be managed by executives and research and development scientific staff with extensive experience in these areas.

In this new phase, Logiq presents itself as specializing in drug development, medical devices and remote monitoring, and rare disease modalities. It states that its mission is to discover, manage, and support companies that share its vision of advancing health through advanced technology and research. The company also highlights longevity medicine, describing an approach that uses AI to understand aging and support treatments aimed at extending healthy lifespan.

MedLab Essentials Acquisition and Cell & Gene Therapy Focus

A key step in Logiq's strategic shift is its definitive agreement to acquire MedLab Essentials, LLC, a company described as a trailblazer in cell and gene therapy innovation. MedLab is portrayed as an advanced biotechnology company focused on the development and manufacturing of cell-based therapy products for various human indications, including hard-to-treat cancers, osteoarthritis, and age-related diseases. Its platform uses autologous adipose-derived mesenchymal stem cells combined with oncolytic viruses and therapeutic components.

Under the announced transaction, MedLab is to become a wholly owned subsidiary of Logiq, with key MedLab executives expected to join Logiq's senior management team. Company disclosures describe this acquisition as the first in a planned series of biotech and cell and gene therapy asset acquisitions, with the goal of building a portfolio of health-related businesses. Logiq also notes that it aims to pursue additional acquisitions in biotech and related sectors.

Medical Devices and Remote Patient Monitoring

Logiq has also announced a definitive agreement to acquire EVIMATE, characterized as a pioneer in medical device innovation. EVIMATE is described as developing a suite of vital sign monitoring products that use advanced AI technology for comprehensive monitoring and predictive analytics across metrics such as temperature, heart rate, ECG, blood pressure, oxygen levels, and glucose levels. These devices are designed to work with a user-friendly app and to meet remote patient monitoring standards, providing real-time insights and alerts to healthcare providers, caregivers, and family members.

In addition to clinical and home settings, company materials state that EVIMATE has developed automotive healthcare systems to monitor driver or pilot vital signs using multiple embedded sensors. All such devices are described as subject to regulatory approvals, including U.S. Food and Drug Administration (FDA) review, and the company notes that additional patents are expected to be filed for intellectual property protection.

Veterinary and Animal Health Products

Through its acquisition of MedLab Essentials, Logiq also gained Amino Medic Ltd., which the company describes as part of MedLab's original acquisition. Amino Medic brings expertise in peptides, cell and gene therapies, and human health technologies. Within this structure, Logiq highlights a veterinarian division that has launched AVR BIOVET™, also referred to as GrowthMax, a copper-based organic feed additive intended to support the health and growth of home pets and farm animals.

Company communications describe AVR BIOVET™ as a product featuring nanoparticles of copper, essential amino acids, vitamins, and probiotics. It is presented as an additive for nursing and weaned diets, available in liquid and solid forms, and capable of being mixed into water or dry food. Logiq states that AVR BIOVET™ is designed to support optimal development, strengthen the immune system, enhance nutrient absorption, and provide antibacterial, antiviral, and antistress properties. It is also described as potentially supplementing or replacing certain antibiotics and antibacterial substances in breeding cycles, with the company indicating plans to seek FDA and U.S. Department of Agriculture (USDA) approvals and to file additional patents before manufacturing.

Legacy Digital Advertising and DataLogiq (DLQ)

Before its strategic shift toward health and biotech, Logiq emphasized its role as a digital consumer acquisition and e-commerce solutions provider. The company describes its DataLogiq (DLQ) business as offering data-driven, end-to-end marketing, including a self-serve ad tech platform and AI-powered tools that enable brands and agencies to advertise across a large number of digital and connected TV publishers.

Logiq has reported that its programmatic advertising platform incorporates AI-powered fraud detection and analytics. According to company statements, this system uses advanced algorithms and machine learning techniques to analyze data points such as user behavior, IP addresses, device information, and traffic sources in order to identify click fraud, impression fraud, and traffic manipulation. The platform is described as adaptive, learning from new fraud patterns, and providing reporting and analytics that help advertisers evaluate campaign quality and attribute conversions across multiple touchpoints.

The company has also highlighted a SPAC-related initiative involving its DLQ subsidiary and Abri SPAC I, Inc. In that context, DLQ is described as a provider of e-commerce and digital customer acquisition solutions that simplify digital advertising, with a focus on data-driven marketing and a proprietary, AI-powered platform.

Business Model Elements Described by the Company

Across its disclosures, Logiq outlines several core business activities:

• Drug Development: Focusing on therapies that address unmet medical needs, particularly within cell and gene therapy, longevity, anti-aging, and life extension.
• Medical Devices and Remote Monitoring: Developing and supporting devices and platforms, such as those of EVIMATE, aimed at continuous vital sign monitoring and predictive analytics.
• Rare Diseases: Exploring treatment approaches for challenging conditions, including certain cancers and age-related diseases, through cell-based therapy platforms.
• Strategic Partnerships: Engaging in collaborations that involve shared research, technological resources, and potential equity stakes to support health innovation.
• Sales and Marketing Support: Providing backing to portfolio companies to help them compete in their respective markets.
• Human Resources Development: Building a workforce aligned with the company's health and technology objectives.

Corporate Initiatives and Capital Markets Strategy

Logiq has communicated plans related to capital raising and stock exchange listings. In connection with the MedLab and EVIMATE transactions, the company has discussed objectives such as securing significant capital infusions and seeking to meet listing qualifications for exchanges such as Nasdaq, Cboe, or the New York Stock Exchange. It has also referenced targeting multiple additional strategic acquisitions in biotech and related sectors.

In earlier updates, Logiq described a merger transaction involving its DLQ subsidiary and Abri SPAC I, Inc., with a proposed combined company name of Collective Audience, Inc. and an expected Nasdaq listing under new ticker symbols, subject to regulatory and shareholder approvals and other customary closing conditions.

Research and Development Footprint

As part of the MedLab and Amino Medic structure, Logiq notes that its Chief Medical Officer and founder of Amino Medic, Dr. Mark Litvak, maintains an office and staff in Tel Aviv, Israel. This team is described as responsible for ongoing research and development focused on animal and human health applications, including potential future product lines based on the AVR platform.

How Logiq Describes Its Competitive Approach

In its health and biotech narrative, Logiq emphasizes access to proprietary laboratory technology, cell-based therapy platforms, and AI tools. The company presents its strategy as integrating research and development with commercialization, and as building a network of entities connected through strategic partnerships and equity arrangements. In its digital advertising legacy business, Logiq highlights AI-powered fraud detection, privacy-centric tracking, and the ability to support campaigns across many publishers.

FAQs about Logiq, Inc. (LGIQ)

• What does Logiq, Inc. do?
  Logiq, Inc. describes itself as a technology company that has transitioned from e-commerce and digital customer acquisition solutions into the medical field. The company reports activities in drug development, medical devices and remote monitoring, rare disease modalities, cell and gene therapy, longevity and anti-aging, as well as animal health products.
• How did Logiq's business model evolve?
  Company communications state that Logiq was previously engaged in e-commerce solutions and services and provided digital consumer acquisition solutions through its DataLogiq (DLQ) operations. It reports that it recently sold part of its technology business and decided to change direction by targeting the medical field, including cell and gene therapy and longevity-related treatments.
• What is MedLab Essentials and how is it related to Logiq?
  MedLab Essentials, LLC is described as a company focused on cell and gene therapy innovation and the development of cell-based therapy products for various human indications. Logiq announced a definitive agreement to acquire MedLab through a share exchange, with MedLab expected to become a wholly owned subsidiary and its executives joining Logiq's senior management team.
• What is EVIMATE and why is it important to Logiq?
  EVIMATE is characterized by Logiq as a pioneer in medical device innovation, developing AI-enabled vital sign monitoring products and remote patient monitoring solutions. Logiq announced a definitive agreement to acquire EVIMATE, with the business expected to integrate as a wholly owned subsidiary and its executives joining Logiq's senior management.
• What is AVR BIOVET™?
  AVR BIOVET™, also referred to as GrowthMax, is described by Logiq as a copper-based organic feed additive developed within its veterinarian division, associated with Amino Medic Ltd. The product is intended to support growth, immune function, and overall health in animals, with company materials citing antibacterial, antiviral, and antistress properties and potential use as a supplement or partial replacement for certain antibiotics and antibacterial substances in breeding cycles.
• How does Logiq use artificial intelligence?
  In its legacy digital advertising business, Logiq reports using AI-powered algorithms and machine learning to detect and prevent digital advertising fraud, analyze user behavior, and provide analytics for campaign optimization. In its health and longevity narrative, the company states that it uses advanced AI to analyze aspects of aging and to support personalized approaches to longevity medicine.
• What role does DataLogiq (DLQ) play within Logiq?
  DataLogiq (DLQ) is described as Logiq's digital marketing and e-commerce customer acquisition business. It offers data-driven marketing, a self-serve ad tech platform, and AI-powered tools for advertising across digital and connected TV publishers. DLQ has also been the subject of a proposed SPAC merger with Abri SPAC I, Inc., as described in company filings and press releases.
• Where is Logiq headquartered?
  Company descriptions state that Logiq Inc. is headquartered in the United States. Additional locations mentioned in relation to research and development activities include Tel Aviv, Israel, where a medical team associated with Amino Medic Ltd. is based.
• What sectors does Logiq target in its health-related strategy?
  Logiq identifies several focus areas: cell and gene therapy, longevity and anti-aging, rejuvenation, rare diseases, drug development, medical devices and remote patient monitoring, and animal health products such as AVR BIOVET™.
• Is Logiq still involved in digital advertising?
  Logiq continues to describe its capabilities in e-commerce and digital customer acquisition, including its AI-powered programmatic ad platform and fraud detection technology. At the same time, the company has stated that it sold part of its technology business and is redirecting its primary strategic focus toward medical and biotech sectors.